Quantifying T cell exhaustion: An insight into BiTE antibodies and CAR-T cells for improved therapeutics
T cell exhaustion is recognized as a major challenge in the development of immuno-oncology therapies. It describes the loss of effector function due to chronic antigen exposure, and often occurs within the tumor microenvironment, impairing the ability of T cells to eradicate cancerous cells effectively.
The development of tumor-specific immunotherapies focuses on overcoming this exhausted phenotype of T cells, to allow targeted killing of the tumor.
Attend this expert webinar to:
- Gain unique insights into how bispecific T cell engager (BiTE) antibodies in an immune cell killing assay affect T cell exhaustion
- Explore the influence of target cells on CAR-T cell exhaustion
- Learn how to use an advanced flow cytometry platform to quantify T cell exhaustion phenotypes and cytokine release
Who should attend?
Immuno-oncology, cancer immunotherapy drug discovery and immunology researchers in pharma, biopharma and academia.